Morepen Laboratories Ltd (MOREPENLAB) is currently trading at 106.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Morepen Laboratories is an India-based integrated pharmaceutical and medical-device company producing APIs, formulations and point-of-care medical devices with a product mix split roughly 62% pharma (API+Rx) and 38% medical devices, and manufacturing sites including a USFDA-approved facility and a hi-tech pharma complex in Himachal Pradesh. Financial momentum in Q3 FY26 shows consolidated gross revenue of Rs. 488 crores and standalone gross revenue of Rs. 462 crores with strong sequential improvement: consolidated PAT rose 83% year-on-quarter (Q2 to Q3) and standalone PAT increased 77%, reflecting operating leverage and non-recurring income components in the quarter. Medical devices are the primary growth engine: device revenue grew 44% year-on-year in Q3 and 18% over 9M, driven by glucometers which now represent 76% of device revenue, cumulative sales of 16.85 million meters and 2.33 billion strips, indicating scale in consumables and recurring revenue streams. Pharma/API revenue is stagnating: total pharma revenue declined 3% over 9M and API revenue fell 5% year-on-year, with APIs concentrated in a few molecules (Atorva, Lorata+Des, Monte) and a higher share of sales in Europe and India, while the U.S. share remains low at 3% of quarterly revenue. Geographic mix is shifting toward domestic demand, with India rising to 64.1% of Q3 revenue and the U.S. contribution contracting; this concentration amplifies domestic opportunity but also raises exposure to India-specific pricing, distribution and regulatory dynamics that management must navigate.

Over the past 52 weeks, Morepen Laboratories Ltd has traded between a low of ₹33.44 and a high of ₹122.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Morepen Laboratories Ltd has a market capitalization of approximately 6,353.52. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Morepen Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 6,353.52 Cr, Morepen Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Morepen Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Morepen Laboratories Ltd is 45.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The Board of Directors meeting is scheduled for August 4, 2026 to consider and approve Q1 FY27 results.

Morepen said the CDMO mandate is valued at approximately ₹825 crore, also reported as USD 91 million, from a leading global pharma major.

Morepen reported Q4 FY26 gross revenue of ₹472 crore (+22% YoY) and net profit of ₹20 crore (+69% YoY) in its quarterly narrative.

Revenue from operations rose 10.11% year-on-year to Rs 465.85 crore, while consolidated net profit fell 29.33% to Rs 20.31 crore.